HRMY is a relatively new company in the biotech space and has held up incredibly well since it's IPO in 2020, forming a nice 2 year base. Price is currently sat just under $54 above which are clear skies. The weekly chart shows an up/down ratio of over 2, suggesting significant institutional accumulation
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.